



WHAT IS CLAIMED IS:

1. A compound of the formula (I) or (II):



wherein

m is an integer from 0 to 1;

- 10 with the proviso that if m is 0 or 1, then

“HET” in the compound of formula (II) is a stable five- or six-membered monocyclic aromatic ring system composed of carbon atoms and one heteroatom, wherein the heteroatom is selected from the group consisting of N, O and S which may occupy any position in the ring whereby the resulting

15 ring system is stable;

A is selected from the group consisting of -C(O)-, SO₂ and CH₂;

Y is selected from the group consisting of CH₂ and CH as part of an olefin;

20

X is selected from the group consisting of CH₂, CH as part of an olefin, NR₃, S and O;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an

25 olefin;

Z is selected from the group consisting of N and CH;

R₁ is one to two substituents independently selected from the group consisting

of hydrogen, alkyl, alkoxy, halogen, aminoalkyl, oxo and nitro;

Ar is selected from naphthyl, wherein naphthyl is optionally substituted with from one to four substituents independently selected from C₁-C₈ alkyl, C₁-C₈ alkoxy, fluorinated C₁-C₈ alkyl, fluorinated C₁-C₈ alkoxy, halogen, cyano, hydroxy, amino, nitro, C₁-C₄ alkylamino or C₁-C₄ dialkylamino (wherein the alkyl groups on the amino may be the same or different); or phenyl, wherein phenyl is optionally substituted with from one to four substituents independently selected from C₁-C₈ alkyl, C₁-C₈ alkoxy, fluorinated C₁-C₈ alkyl, fluorinated C₁-C₈ alkoxy, C₁-C₈ aralkyl (wherein optionally the alkyl or aryl portions are independently substituted and the alkyl portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C₁-C₄ alkyl, C₁-C₆ alkylthio or hydroxyl), C₁-C₈ aralkoxy (wherein optionally the alkoxy or aryl portions are independently substituted and the alkoxy portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C₁-C₄ alkyl, C₁-C₆ alkylthio or hydroxyl), halogen, cyano, hydroxy, amino, nitro, C₁-C₈ alkylamino, C₁-C₄ dialkylamino (wherein the alkyl groups on the amino may be the same or different), (halo)₁₋₃(C₁-C₈)alkylthio, C₁-C₈ alkylsulfonyl, C₁-C₈ alkylthio, C₁-C₈ alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from C₁-C₈ alkyl) or phenyl (optionally substituted with from one to two substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, fluorinated C₁-C₄ alkyl, fluorinated C₁-C₄ alkoxy, halogen, cyano, hydroxy, amino, nitro, C₁-C₄ alkylamino, C₁-C₄ dialkylamino (wherein the alkyl groups on the amino may be the same or different), C₁-C₄ alkylsulfonyl, C₁-C₄ alkylthio, or C₁-C₄ alkylsulfinyl);

R₂ is selected from the group consisting of NR₄COAr, NR₄CO-heteroaryl, NR₄Ar, CH=CH-Ar, CF=CH-Ar, CH=CF-Ar, CCl=CH-Ar, CH=CCl-Ar, CH=CH-heteroaryl, CF=CH-heteroaryl, CH=CF-heteroaryl, -CCl=CH-heteroaryl, CH=CCl-heteroaryl, OCH₂-Ar, OCH₂-heteroaryl, SCH₂-Ar and NR₄CH₂Ar;

R₃ is selected from the group consisting of hydrogen, acyl, alkyl, alkoxycarbonyl, alkylsulfonyl and arylsulfonyl;

R₄ is selected from the group consisting of hydrogen and C₁-C₄ alkyl;

5

R₅ is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different); trifluoromethyl and trifluoromethoxy;

10 and pharmaceutically acceptable salts thereof.

2. The compound of Claim 1 wherein

"HET" is selected from the group consisting of thiophene, furan, pyrrole and pyridine;

15

A is -C(O)-;

Ar is naphthyl, wherein naphthyl is optionally substituted with from one to four substituents independently selected from trifluoromethyl, trifluoromethoxy, -NH-C₁-C₄ alkyl or -N-(C₁-C₄ alkyl)₂ (wherein the alkyl groups on the amino may be the same or different);

20

R₂ is NR₄COAr;

25 R₄ is selected from the group consisting of hydrogen and methyl;


and pharmaceutically acceptable salts thereof.

3. The compound of Claim 1 wherein

30 R₄ is hydrogen;

and pharmaceutically acceptable salts thereof.

4. The compound of Claim 1 of the formula (III):



5 wherein

Y is selected from the group consisting of CH₂ and CH as part of an olefin;

X is selected from the group consisting of CH₂, CH as part of an olefin, NR₃, S and O;

10

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

R₁ is one to two substituents independently selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, halogen, amino C₁-C₄ alkyl, oxo and nitro;

15

R₂ is NHCOAr;

R₃ is selected from the group consisting of hydrogen, acyl, C₁-C₄ alkyl, C₁-C₄ alkylsulfonyl and arylsulfonyl;

20

R₅ is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;

25

and pharmaceutically acceptable salts thereof.

5. The compound of Claim 4 wherein

Y is selected from the group consisting of CH₂ and CH as part of an olefin;

X is selected from the group consisting of CH₂, CH as part of an olefin, O and S;

5

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

A is -C(O)-;

10


Z is CH;

Ar is phenyl, wherein phenyl is optionally substituted with from one to four substituents independently selected from C₁-C₈ alkyl, C₁-C₈ alkoxy, fluorinated C₁-C₈ alkyl, fluorinated C₁-C₈ alkoxy, C₁-C₈ aralkyl (wherein optionally the alkyl or aryl portions are independently substituted and the alkyl portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C₁-C₄ alkyl, C₁-C₆ alkylthio or hydroxyl), C₁-C₈ aralkoxy (wherein optionally the alkoxy or aryl portions are independently substituted and the alkoxy portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C₁-C₄ alkyl, C₁-C₆ alkylthio or hydroxyl), halogen, cyano, hydroxy, amino, nitro, C₁-C₈ alkylamino, C₁-C₄ dialkylamino (wherein the alkyl groups on the amino may be the same or different), (halo)₁₋₃(C₁-C₈)alkylthio, C₁-C₈ alkylsulfonyl, C₁-C₈ alkylthio, C₁-C₈ alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from C₁-C₈ alkyl) or phenyl (optionally substituted with from one to two substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, fluorinated C₁-C₄ alkyl, fluorinated C₁-C₄ alkoxy, halogen, cyano, hydroxy, amino, nitro, C₁-C₄ alkylamino, C₁-C₄ dialkylamino (wherein the alkyl groups on the amino may be the same or different), C₁-C₄ alkylsulfonyl, C₁-C₄ alkylthio, or C₁-C₄ alkylsulfinyl);

and pharmaceutically acceptable salts thereof.

6. A compound of the formula (IV):

5



Formula (IV)

wherein

10 X is selected from the group consisting of CH₂, S and O;

R₁ is one to two substituents independently selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, halogen, amino C₁-C₄ alkyl, oxo and nitro;

15

R₅ is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;


20 R₆ is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, phenyl (wherein the phenyl is optionally substituted with from one to two substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, fluorinated

C₁-C₄ alkyl, fluorinated C₁-C₄ alkoxy, halogen, cyano, hydroxy, amino, nitro, C₁-C₄ alkylamino, C₁-C₄ dialkylamino (wherein the alkyl groups on the amino may be the same or different), C₁-C₄ alkylsulfonyl, C₁-C₄ alkylthio, or C₁-C₄ alkylsulfinyl); aralkyl (wherein the alkyl or aryl portions are optionally
 5 independently substituted and the alkyl portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C₁-C₄ alkyl, C₁-C₆ alkylthio or hydroxyl), aralkoxy (wherein the alkoxy or aryl portions are optionally independently substituted and the alkoxy portion may be substituted with at least
 10 one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C₁-C₄ alkyl, C₁-C₆ alkylthio or hydroxyl), heteroaryl (optionally substituted with one to two substituents independently selected from C₁-C₄ alkyl or halogen), heteroaryl(C₁-C₈)alkyl (wherein the heteroaryl portion is optionally substituted with one to two
 15 substituents selected from C₁-C₈ alkyl), (halo)₁₋₃(C₁-C₄)alkylthio and halogen; and

R₇ is independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, fluorinated C₁-C₆ alkyl and
 20 combinations thereof, wherein R₇ represent one to four independently selected groups;

and pharmaceutically acceptable salts thereof.

25 7. The compound of Claim 6 wherein the compound of formula (IV) is selected from a compound of formula (IVa):



Formula (IVa)

wherein

Y is selected from the group consisting of CH₂ and CH as part of an olefin;


X is selected from the group consisting of CH₂, CH as part of an olefin, S and
 5 O;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an
 olefin;

10 R₅ is one to two substituents independently selected from the group consisting
 of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, chlorine, fluorine, hydroxy, dialkylamino
 (wherein the alkyl groups may be the same or different), trifluoromethyl and
 trifluoromethoxy;

15 and pharmaceutically acceptable salts thereof.

8. A compound of formula (I):



wherein

A is selected from the group consisting of $-C(O)-$, SO_2 and CH_2 ;

5

Y is selected from the group consisting of CH_2 and CH as part of an olefin;

X is selected from the group consisting of CH_2 , CH as part of an olefin, NR_3 , S , O and SO_2 ;

10

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

Z is selected from the group consisting of N and CH ;

15

R_1 is one to two substituents independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, aminoalkyl, oxo and nitro;

R_2 is selected from the group consisting of NR_4COAr , NR_4CO -heteroaryl, NR_4Ar , $CH=CH-Ar$, $CF=CH-Ar$, $CH=CF-Ar$, $CCl=CH-Ar$, $CH=CCl-Ar$, $CH=CH$ -heteroaryl, $CF=CH$ -heteroaryl, $CH=CF$ -heteroaryl, $-CCl=CH$ -heteroaryl, $CH=CCl$ -heteroaryl, OCH_2-Ar , OCH_2 -heteroaryl, SCH_2-Ar and NR_4CH_2Ar ;

R_3 is selected from the group consisting of hydrogen, acyl, alkyl, aralkyl, alkoxy, carbonyl, alkylsulfonyl, fluorinated alkyl and arylsulfonyl;

25

Ar is selected from the group consisting of naphthyl, wherein naphthyl is optionally substituted with from one to four substituents independently selected from the group consisting of C_1 - C_8 alkyl, C_1 - C_8 alkoxy, fluorinated C_1 - C_8 alkyl,

fluorinated C₁-C₈ alkoxy, halogen, cyano, hydroxy, amino, nitro, C₁-C₄ alkylamino and C₁-C₄ dialkylamino (wherein the alkyl groups on the amino may be the same or different); and phenyl, wherein phenyl is optionally substituted with from one to four substituents independently selected from C₁-C₈ alkyl, C₁-C₈ alkoxy, fluorinated C₁-C₈ alkyl, fluorinated C₁-C₈ alkoxy, C₁-C₈ aralkyl (wherein the alkyl portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₆ alkylthio and hydroxy), C₁-C₈ aralkoxy (wherein the alkoxy portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₆ alkylthio and hydroxy), halogen, cyano, hydroxy, amino, nitro, C₁-C₈ alkylamino, C₁-C₄ dialkylamino (wherein the alkyl groups on the amino may be the same or different), C₁-C₈ alkylsulfonyl, C₁-C₈ alkylthio, (halo)₁₋₃(C₁-C₈)alkylthio, C₁-C₈ alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C₁-C₈ alkyl and halogen), heteroaryl(C₁-C₈)alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents independently selected from C₁-C₈ alkyl) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, fluorinated C₁-C₄ alkyl, fluorinated C₁-C₄ alkoxy, halogen, cyano, hydroxy, amino, nitro, C₁-C₄ alkylamino, C₁-C₄ dialkylamino (wherein the alkyl groups on the amino may be the same or different), C₁-C₄ alkylsulfonyl, C₁-C₄ alkylthio and C₁-C₄ alkylsulfinyl);

25

R₄ is selected from the group consisting of hydrogen and C₁-C₄ alkyl;

R₅ is one to two substituents independently selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;

30

and pharmaceutically acceptable salts thereof.

9. The compound of claim 8 wherein A is -C(O)-.
10. The compound of claim 8 wherein Z is CH.
- 5 11. The compound of claim 8 wherein R₁ is one to two substituents independently selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, halogen and oxo.
- 10 12. The compound of claim 8 wherein R₁ is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, chlorine, fluorine and oxo.
- 15 13. The compound of claim 8 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C₁-C₈ alkyl, C₁-C₈ alkoxy, fluorinated C₁-C₈ alkyl, fluorinated C₁-C₈ alkoxy, C₁-C₈ aralkyl (wherein the alkyl portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents independently
- 20 selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₆ alkylthio and hydroxy), C₁-C₈ aralkoxy (wherein the alkoxy portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents independently
- 25 selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₆ alkylthio and hydroxy), halogen, cyano, hydroxy, amino, nitro, C₁-C₈ alkylamino, C₁-C₄ dialkylamino (wherein the alkyl groups on the amino may be the same or different), C₁-C₈ alkylsulfonyl, C₁-C₈ alkylthio, (halo)₁₋₃(C₁-C₈)alkylthio, C₁-C₈ alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from the
- 30 group consisting of C₁-C₈ alkyl and halogen), heteroaryl(C₁-C₈)alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents independently selected from C₁-C₈ alkyl) and phenyl (optionally substituted with from one to two substituents independently

- selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, fluorinated C₁-C₄ alkyl, fluorinated C₁-C₄ alkoxy, halogen, cyano, hydroxy, amino, nitro, C₁-C₄ alkylamino, C₁-C₄ dialkylamino (wherein the alkyl groups on the amino may be the same or different), C₁-C₄ alkylsulfonyl, C₁-C₄ alkylthio and C₁-C₄ alkylsulfinyl).
14. The compound of claim 8 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C₁-C₈ alkyl, C₁-C₈ alkoxy, fluorinated C₁-C₈ alkyl, halogen, hydroxy, (halo)₁₋₃(C₁-C₈)alkylthio, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C₁-C₈ alkyl and halogen) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, halogen and hydroxy).
15. The compound of claim 8 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, fluorinated C₁-C₄ alkyl, halogen, hydroxy, (halo)₁₋₃(C₁-C₄)alkylthio, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C₁-C₄ alkyl and halogen) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, halogen and hydroxy).
16. The compound of claim 8 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, fluorinated C₁-C₄ alkyl, halogen, hydroxy and (halo)₁₋₃(C₁-C₄)alkylthio; and, optionally substituted with from one to two substituents independently selected from the group consisting of heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of

C₁-C₄ alkyl and halogen) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, halogen and hydroxy).

- 5 17. The compound of claim 8 wherein R₂ is selected from the group consisting of NR₄COAr, NR₄CO-heteroaryl, NR₄Ar, CH=CH-Ar, CF=CH-Ar, CH=CF-Ar, CCl=CH-Ar, CH=CCl-Ar, CH=CH-heteroaryl, CF=CH-heteroaryl, CH=CF-heteroaryl, -CCl=CH-heteroaryl, CH=CCl-heteroaryl and NR₄CH₂Ar.
- 10 18. The compound of claim 8 wherein R₂ is selected from NR₄COAr.
19. The compound of claim 8 wherein R₂ is selected from NHCOAr.
- 15 20. The compound of claim 8 wherein R₃ is selected from the group consisting of hydrogen, acyl, C₁-C₈ alkyl, ar(C₁-C₈)alkyl, C₁-C₈ alkoxy carbonyl, C₁-C₈ alkylsulfonyl, fluorinated(C₁-C₈) alkyl and arylsulfonyl.
- 20 21. The compound of claim 8 wherein R₃ is selected from the group consisting of hydrogen, acyl, C₁-C₄ alkyl, ar(C₁-C₄)alkyl and trifluoro(C₁-C₄)alkyl.
- 25 22. The compound of claim 8 wherein R₃ is selected from the group consisting of hydrogen, formyl, methyl, isopropyl, benzyl and trifluoroethyl.
- 30 23. The compound of claim 8 wherein R₅ is one to two substituents independently selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy.

24. The compound of claim 8 wherein R_5 is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, chlorine, fluorine, hydroxy, dimethylamino and trifluoromethyl.
- 5 25. The compound of claim 6 wherein R_6 is selected from the group consisting of hydrogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, phenyl (wherein the phenyl is optionally substituted with from one to two substituents independently selected from the group consisting of C_1 - C_4 alkyl, C_1 - C_4 alkoxy, fluorinated C_1 - C_4 alkyl, fluorinated C_1 - C_4 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1 - C_4 alkylamino, C_1 - C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1 - C_4 alkylsulfonyl, C_1 - C_4 alkylthio and C_1 - C_4 alkylsulfinyl); heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C_1 - C_4 alkyl and halogen), heteroaryl(C_1 - C_8)alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents independently selected from C_1 - C_8 alkyl), (halo)₁₋₃(C_1 - C_4)alkylthio and halogen.
- 10 26. The compound of claim 6 wherein R_6 is selected from the group consisting of hydrogen, C_1 - C_4 alkyl, phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C_1 - C_4 alkyl, C_1 - C_4 alkoxy, halogen and hydroxy), heteroaryl (optionally substituted with one to two substituents independently selected from C_1 - C_4 alkyl), (halo)₁₋₃(C_1 - C_4)alkylthio and halogen.
- 15 27. The compound of claim 6 wherein R_6 is selected from the group consisting of hydrogen, methyl, phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of methyl, methoxy, fluorine and hydroxy), thienyl (optionally substituted with methyl), difluoromethylthio, fluorine, chlorine and iodine.
- 20 28. The compound of claim 6 wherein R_7 is one to three substituents independently selected from the group consisting of hydrogen, fluorine,
- 25 30

chlorine, iodine, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy and fluorinated C₁-C₆ alkyl.

29. The compound of claim 6 wherein R₇ is one to three substituents
 5 independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxy, C₁-C₄ alkyl, C₁-C₄ alkoxy and fluorinated C₁-C₄ alkyl.
30. The compound of claim 6 wherein R₇ is one to three substituents
 10 independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxy, C₁-C₂ alkyl, C₁-C₂ alkoxy and fluorinated C₁-C₂ alkyl.
31. The compound of claim 6 wherein R₇ is one to three substituents
 15 independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxy, methyl, methoxy and trifluoromethyl.
32. The compound of Claim 1 selected from the group consisting of
- 20 10-[4-[[[(2-Biphenyl)carbonyl]amino]benzoyl]-10,11-dihydro-5H-piperidino[2,1-c][1,4]benzodiazepine;
- 10-[4-[[[(2-Biphenyl)carbonyl]amino]benzoyl]-10,11-dihydro-5H-(tetrahydropyridino)[2,1-c] [1,4]benzodiazepine;
- 25 (RS)-2-Phenyl-N-[4-(1,3,4,12a-tetrahydro-6H-[1,4]thiazino[4,3-a][1,4]-benzodiazepin-11(12H)-yl-carbonyl)phenyl]benzamide;
- (S)-2-Phenyl-N-[3-chloro-4-(1,3,4,12a-tetrahydro-6H-[1,4]oxazino[4,3-a][1,4]-benzodiazepin-11(12H)-yl-carbonyl)phenyl]benzamide;
- 30 (S)-2-(4-Hydroxyphenyl)-N-[3-chloro-4-(1,3,4,12a-tetrahydro-6H-[1,4]oxazino[4,3-a][1,4]-benzodiazepin-11(12H)-yl-carbonyl)phenyl]benzamide;

(S)-2-Phenyl-4-hydroxy-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

5 (S)-2-(3-Hydroxyphenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(S)-2-Phenyl-5-hydroxy-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

10

(*RS*)-2-(4-Methyl-2-thienyl)-4-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,6-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-
15 *a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-
a][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

20 (*RS*)-2-(4-Methyl-phenyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-
a][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*R*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-
benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

25

(*RS*)-2-Phenyl-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-
a][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[2-methoxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-
30 *a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3,4,5-Tetrafluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-
a][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Chloro-5-trifluoromethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

5 (*RS*)-2-Fluoro-3-chloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(Difluoromethylthio)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

10

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-5-oxo-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

15

(*RS*)-2-Phenyl-*N*-[2-hydroxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

20 (*RS*)-2-Phenyl-*N*-[3-hydroxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

25

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

30

(*RS*)-2-Methyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

- 5 (*RS*)-2-Phenyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

10

(*RS*)-2-Phenyl-*N*-[4-(8-methoxy-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

- 15 (*RS*)-2-Phenyl-*N*-[4-(8-fluoro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(9-chloro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

- 20 (*RS*)-2-Phenyl-*N*-[4-(8,9-difluoro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8-methyl-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

25

(*RS*)-2-Phenyl-*N*-[4-(8-chloro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

- 30 (*RS*)-2-Phenyl-*N*-[3-chloro-4-(8-fluoro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(10-methyl-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-3,5-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

5 (*RS*)-2-Iodo-3-methyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-3,5-Dichloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

10

(*RS*)-2-Methyl-3-iodo-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(2-Fluoro-phenyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

15

(*S*)-2-Phenyl-*N*-[3-dimethylamino-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

20 (*S*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

and pharmaceutically acceptable salts thereof.

25 33. The compound of Claim 1 selected from the group consisting of

10-[4-[[[(2-Biphenyl)carbonyl]amino]benzoyl]-10,11-dihydro-1,2-methanopyrrolidino[2,1-*c*][1,4]benzodiazepine;

30 (*RS*)-2-(3-Thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Thienyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-

a)[1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Thienyl)-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-
a)[1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

5

(*RS*)-2-(2-Thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-
benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-2-thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-
10 a)[1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-2-thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-
a)[1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2,2-dioxo-6*H*-[1,4]thiazino[4,3-*a*][1,4]-
15 benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-
[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-
20 carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2-benzyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-
benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-
25 benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2-formyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-
benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

30

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-isopropyl-6*H*-
[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-
carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-
[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-
carbonyl)phenyl]benzamide;

5

(*RS*)-2,3-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-
[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-
carbonyl)phenyl]benzamide;

10 (*RS*)-2,6-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-
[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-
carbonyl)phenyl]benzamide;

15 (*RS*)-2-(4-Methyl-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-
[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-
carbonyl)phenyl]benzamide;

20 (*RS*)-2-(4-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-
[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-
carbonyl)phenyl]benzamide;

25 (*RS*)-2-(3-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-
[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-
carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-
a][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

30 (*RS*)-2-Phenyl-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-
[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-
carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[2-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-

[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[2-methoxy-4-(1,3,4,12*a*-tetrahydro-2-methyl-6*H*-
5 [1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-trifluoromethyl-4-(1,3,4,12*a*-tetrahydro-2-methyl-6*H*-
10 [1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[2-methyl-4-(1,3,4,12*a*-tetrahydro-2-methyl-6*H*-
[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

15 (*RS*)-2-Methyl-*N*-[3-methoxy-4-(1,3,4,12*a*-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

20 (*RS*)-2-Phenyl-*N*-[3-methoxy-4-(1,3,4,12*a*-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-methoxy-4-(1,3,4,12*a*-tetrahydro-2-methyl-6*H*-
25 [1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[4-(1,3,4,12*a*-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

30 (*RS*)-2-Phenyl-*N*-[3-methyl-4-(1,3,4,12*a*-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

- (*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-(2,2,2-trifluoroethyl)-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;
- 5
- (*RS*)-2,3,4,5-Tetrafluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;
- 10
- (*RS*)-2-Methyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;
- (*RS*)-2-Methyl-3-chloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;
- 15
- (*RS*)-2,3-Dichloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;
- 20
- (*RS*)-2,6-Dichloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;
- 25
- (*RS*)-2-Phenyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;
- (*RS*)-2-Methyl-3-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;
- 30

(*RS*)-2-Phenyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-
[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-4-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-
5 [1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-
benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

10 (*RS*)-2-Phenyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-
benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-
a][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

15 (*RS*)-2-Phenyl-*N*-[3-hydroxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-
a][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-
20 [1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-
[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

25 (*RS*)-2-(4-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-
[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-
[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;


30 (*RS*)-2-Phenyl-4-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-
[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-4-methoxy-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-
[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;


(*RS*)-2-Phenyl-5-methoxy-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-
5 [1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

and pharmaceutically acceptable salts thereof.


34. A compound of the formula (V):




35. A compound of the formula (VI):



36. A compound of the formula (VII):




37. A compound of the formula (VIII):



Formula (VIII)

38. A compound of the formula (IX):



Formula (IX)

wherein R_3 is selected from the group consisting of hydrogen, acyl, alkyl, aralkyl, alkoxycarbonyl, alkylsulfonyl, fluorinated alkyl and arylsulfonyl.

39. The compound of claim 38 wherein R_3 is selected from the group consisting of hydrogen, acyl, alkyl, aralkyl and trifluoroalkyl.
40. The compound of claim 38 wherein R_3 is selected from the group consisting of hydrogen, formyl, methyl, isopropyl, benzyl and trifluoroethyl.
41. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1.
42. A pharmaceutical composition made by mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.
43. A pharmaceutical composition made by granulating a compound of Claim 1 and a pharmaceutically acceptable carrier.
44. A pharmaceutical composition comprising a pharmaceutically

acceptable carrier and a compound of Claim 8.

45. A pharmaceutical composition made by mixing a compound of Claim 8 and a pharmaceutically acceptable carrier.
- 5
46. A pharmaceutical composition made by granulating a compound of Claim 8 and a pharmaceutically acceptable carrier.
- 10
47. A method of treating a condition selected from hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 1.
- 15
48. The method of Claim 47, wherein the condition is congestive heart failure.
- 20
49. The method of Claim 47, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.
- 25
50. A method of treating a condition selected from hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 8.
- 30
51. The method of Claim 50, wherein the condition is congestive heart failure.
52. The method of Claim 50, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

53. A method of treating a condition selected from hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 6.
5
54. The method of Claim 53, wherein the condition is congestive heart failure.
10
55. The method of Claim 53, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.
15